



SARAH CANNON

Research Institute

Part of HCA Healthcare UK

Drug Development Programme UK

The Drug Development Programme of Sarah Cannon Research Institute, part of HCA Healthcare UK, offers consistent performance and excellence through a dedicated, experienced oncology drug development team, state-of-the-art clinical trials unit in central London, competitive start-up timelines, and rapid patient accrual within a large referral network.

Our Facility

- CQC-registered oncology trials unit
- On-site pharmacy
- PK testing facilities
- -20 + -80° C freezers
- Refrigerated and non-refrigerated centrifuges
- Cardiac monitoring
- Access to hospital-based critical care services
- Twelve treatment chairs/beds
- Molecular profiling capabilities

For Patients

- Broad clinical trials portfolio (solid and hematological malignancies)
- Patient-centered support services and referrals
- Private areas for treatment
- On-site catering for patients
- Wireless internet and individual patient entertainment systems

For Partners

We are committed to our partners' goals, and we tailor our teams and processes to meet them, ensuring strong science and consistent quality every step of the way. As collaborators, we strive to provide superior insights that contribute to discovery and success.

Our Team of Professionals

We have a fully-staffed nursing and clinical research team including:

- Principal investigators
- Clinical research fellows
- Clinical trial management team
- Quality assurance manager
- Pharmacy team
- Administrative office support
- Laboratory team
- Data entry team

Facility Amenities and History

- 13,000-square-foot, purpose-designed facility
- Registered listed historic building on Harley Street
- Central London location serviced by three main rail stations and Tube

Study Metrics

- More than 100 clinical trials initiated across all study phases and tumor types
- Pre-screened more than 1,400 patients for rare mutations, amplifications or other alterations
- More than 100 new patients treated in 2015

Learn more about us at sarahcannonresearch.co.uk



SARAH CANNON

Research Institute

Part of HCA Healthcare UK

United Kingdom Leadership

We have a fully-staffed nursing and clinical research team, including principal investigators, clinic and research nurses, clinical trial managers, data coordinators, regulatory affairs specialists, pharmacy technicians, and day and evening pharmacokinetic technicians.



Hendrik-Tobias Arkenau, MD, PhD, FRCP

Executive Medical Director, Drug Development Program, Sarah Cannon Research Institute UK

Arkenau has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research Institute UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

Contact Information: (E) tobias.arkenau@sarahcannonresearch.co.uk




Matthew Simmons

Head of Drug Development Unit, Sarah Cannon Research Institute UK

Simmons has extensive operational and commercial experience across all phases of drug development within the pharmaceutical and CRO industries. He has overall responsibility for the day-to-day management of the Sarah Cannon Research Institute UK Drug Development Unit. Simmons received his degree in molecular biology from The University of Manchester in 1994, and joined what was then SmithKline Beecham, working on the clinical development of a novel cytotoxic agent. Immediately before joining Sarah Cannon Research Institute UK, he managed the global commercial operations teams for Worldwide Clinical Trials, a mid-sized, full-service CRO.

Contact Information: (E) matthew.simmons@sarahcannonresearch.co.uk



Above all else, we are committed to the improvement of patient outcomes and advancement of medical science through innovation and quality execution of cancer research.

For more information or to learn more about specific doctors:



1.877.691.7274
asksarah@sarahcannon.com

Learn more about us at sarahcannonresearch.co.uk